Your browser doesn't support javascript.
loading
Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies.
Guo, Qian; Huang, Yusen; Wang, Fangruyue; Fang, Le.
Afiliación
  • Guo Q; Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China.
  • Huang Y; Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China.
  • Wang F; The Third Bethune Hospital of Jilin University, Changchun, China.
  • Fang L; Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China.
Front Immunol ; 14: 1270011, 2023.
Article en En | MEDLINE | ID: mdl-38124751
ABSTRACT
Multi-antibody-positive myasthenia gravis (MG) presentations are relatively rare, often found in older patients, and generally predict a poor prognosis. We report a case of a female patient with generalized MG, testing positive for Titin antibodies (Titin-Ab), ryanodine receptor antibodies (RyR-Ab), and acetylcholine receptor antibodies (AChR-Ab), and resistant to acetylcholinesterase inhibitors. Following unsuccessful traditional therapies, she received Telitacicept, leading to significant improvements. This case underscores Telitacicept's potential efficacy for similar patients and offers insights into the clinical characteristics of multi-antibody MG.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Timoma / Neoplasias del Timo / Miastenia Gravis Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Timoma / Neoplasias del Timo / Miastenia Gravis Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article